Evidence map›Paper›PMID 36419904›Full record

ArticleFrontiers in oncology2022

Therapeutic efficacy of

Mehrdad Khoshnevis, Richard Brown, Sara Belluco, Ilyes Zahi, Luca Maciocco, Catherine Bonnefont-Rebeix, Elodie Pillet-Michelland, Jonathan Tranel, Thierry Roger, Christophe Nennig and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 1 country.

Mehrdad KhoshnevisUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
Richard BrownInserm, UMR1037 CRCT, Toulouse, France.
Sara BellucoUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
Ilyes ZahiAdvanced Accelerator Applications, a Novartis Company, Saint-Genis-Pouilly, France.
Luca MacioccoAdvanced Accelerator Applications, a Novartis Company, Saint-Genis-Pouilly, France.
Catherine Bonnefont-RebeixUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
Elodie Pillet-MichellandUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
Jonathan TranelInserm, UMR1037 CRCT, Toulouse, France.
Thierry RogerUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
Christophe NennigEVEON, 305 rue Aristide Berges, Montbonnot Saint Martin, France.
Patrick OudoireEVEON, 305 rue Aristide Berges, Montbonnot Saint Martin, France.
Lionel MarconInstitut Lumière Matière, UMR CNRS 5306, UCBL, Campus LyonTech - La Doua, Villeurbanne, France.
Olivier TillementInstitut Lumière Matière, UMR CNRS 5306, UCBL, Campus LyonTech - La Doua, Villeurbanne, France.
Cédric LouisNano-H SAS, 305 rue des Fours, Fontaines Saint Martin, France.
Hélène GehanNano-H SAS, 305 rue des Fours, Fontaines Saint Martin, France.
Manuel BardièsInserm, UMR1037 CRCT, Toulouse, France.
Maurizio MarianiAdvanced Accelerator Applications, a Novartis Company, Colleretto Giacosa, France.
Valeria MuzioAdvanced Accelerator Applications, a Novartis Company, Colleretto Giacosa, France.
Jean-Philippe MeunierAdvanced Accelerator Applications, a Novartis Company, Saint-Genis-Pouilly, France.
Charlotte DucheminSubatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.
Nathalie MichelSubatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.
Estelle N'TsibaSubatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.
Ferid HaddadSubatech, CNRS/IN2P3, IMT Atlantique, Université de Nantes, Nantes Cedex, France.
Thierry BuronfosseUniversité de Lyon, VetAgro Sup, Laboratoire de Biologie Médicale, Marcy L'Etoile, France.
Claude CarozzoUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
Frédérique PonceUniversité de Lyon, VetAgro Sup, UR ICE, Marcy L'Etoile, France.
VetAgro Sup · FRNovartis (France) · FRCentre National de la Recherche Scientifique · FRCentre de Recherche en Cancérologie de Toulouse · FRUniversité Claude Bernard Lyon 1 · FRInserm · FRInstitut Lumière Matière · FRNantes Université · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma is considered the most common malignant primary tumor of central nervous system. In spite of the current standard and multimodal treatment, the prognosis of glioblastoma is poor. For this reason, new therapeutic approaches need to be developed to improve the survival time of the glioblastoma patient. In this study, we performed a preclinical experiment to evaluate therapeutic efficacy of

Indexed as

166Hoanimal modelglioblastomamicrobrachytherapyminipigU87 cells

Identifiers

PMID36419904
PMCPMC9677531
OpenAlexW4308439401

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.